Orphan Drug Designation Given to New Mesothelioma CAR T-Cell Therapy
In early 2023, the world-class Hospital of the University of Pennsylvania will open a groundbreaking clinical trial for mesothelioma patients utilizing a next-generation immunotherapy with a novel delivery platform. The U.S. Food and Drug Administration cleared the path in September by granting orphan drug designation for SynKIR-110, a CAR T-cell therapy designed to target solid tumors expressing a specific protein typically found in mesothelioma cancer. By granting the orphan drug designation, the FDA can provide financial incentives such as tax credits for clinical trials and seven years of market exclusivity. It i...
Source: Asbestos and Mesothelioma News - October 5, 2022 Category: Environmental Health Authors: Fran Mannino Source Type: news

Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML?
(MedPage Today) -- For patients with chronic-phase chronic myeloid leukemia (CML), a response-based dose-reduction strategy for ponatinib (Iclusig) may limit its toxicity while maintaining or improving efficacy, a retrospective study suggested... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 29, 2022 Category: Hematology Source Type: news

Consumer Health: Treating leukemia and lymphoma
September is Leukemia and Lymphoma Awareness Month, which makes this a good time to learn about treating some of the most common types of these two diseases. Leukemia Leukemia is cancer of the body's blood-forming tissues, including bone marrow and the lymphatic system. Leukemia usually involves the white blood cells, which are potent infection fighters. They normally grow and divide in an orderly way as your body needs them. But in people with leukemia, the bone marrow produces an excessive… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 27, 2022 Category: Databases & Libraries Source Type: news

Targeting Leukemia with T Cells That Avoid Self-Destruction
Researchers found that naturally-occurring CD7-negative T cells avoid self-destruction and are good effectors in CAR T therapy for T cell blood cancers. (Source: The Scientist)
Source: The Scientist - September 26, 2022 Category: Science Tags: Sponsored Article Source Type: news

Cesarean Section Tied to Higher Risk for Later Leukemia in Offspring
Findings strongest for elective cesarean section and acute lymphoblastic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2022 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Oncology, Pediatrics, Surgery, Journal, Source Type: news

Cesarean Section Tied to Higher Risk for Later Leukemia in Offspring
THURSDAY, Sept. 15, 2022 -- Elective cesarean section (CS) is associated with an increased risk for leukemia in offspring, according to a systematic review and meta-analysis published online Aug. 24 in Hematological Oncology. Yingzhu Yang, from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2022 Category: Pharmaceuticals Source Type: news

Cell-killing cancer therapy shows promise for a devastating autoimmune disorder
Opening a new frontier in fighting autoimmune disease, researchers have successfully treated five lupus patients with a novel cell therapy that turns run-of-the-mill immune cells into specialized hunters of rogue cells helping fuel illness. The patients treated with the new therapy all saw their severe symptoms, including kidney and other organ dysfunction, largely disappear. The results “are phenomenal,” says Betty Diamond, an immunologist and rheumatologist at the Feinstein Institutes for Medical Research who cares for lupus patients and was not involved in the work. Despite her excitement, she cautions that th...
Source: ScienceNOW - September 15, 2022 Category: Science Source Type: news

CAR-T Therapy Effective in Youngest Kids With ALL
(MedPage Today) -- The use of tisagenlecleucel (Kymriah) in children younger than 3 years of age with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) was as effective, and safe, in a retrospective cohort study as it was previously... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 8, 2022 Category: Hematology Source Type: news

Cell therapy could improve bone marrow transplant safety
FINDINGSUCLA researchers report a step forward in the development of an “off-the-shelf” cell therapy that could reduce the severity of graft-versus-host disease in people receiving donor bone marrow transplants for the treatment of blood cancers such as leukemia and lymphoma.The method utilizes rare and powerful immune cells called invariant natural killer T, or iNKT, cells, which can reduce and delay the transplanted cells ’ attacks on healthy tissue without compromising these cells’ cancer-fighting abilities. The iNKT cells are produced from blood-forming stem cells obtained from donated umbilical cord blood and ...
Source: UCLA Newsroom: Health Sciences - September 6, 2022 Category: Universities & Medical Training Source Type: news

Why did it take two years to diagnose Joel Atkinson's leukaemia?
-Father-of-one Joel Atkinson, from Bishop's Stortford in Hertfordshire, pictured with his partner Amy Claire, was hit with severe shoulder and back discomfort in late 2019. (Source: the Mail online | Health)
Source: the Mail online | Health - September 3, 2022 Category: Consumer Health News Source Type: news

Pharmacist who thought heavy period was caused by Covid booster jab diagnosed with leukaemia 
Victoria Lang, 30, from North Lanarkshire, thought her heavy period was caused by a recent Covid booster jab but found out it was actually a sign that she had a rare form of leukaemia (Source: the Mail online | Health)
Source: the Mail online | Health - September 1, 2022 Category: Consumer Health News Source Type: news

At-Risk Groups Underrepresented in Cancer Trials Leading to Approvals
(MedPage Today) -- At-risk populations -- particularly Black and Hispanic patients -- are significantly underrepresented in pivotal clinical trials for leukemias and multiple myeloma, a recent analysis showed. Among 41 trials that led to FDA... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 31, 2022 Category: Hematology Source Type: news

Young Children With Leukemia Are Outliving Teens Young Children With Leukemia Are Outliving Teens
Leukemia survival rates are increasing, but adolescents and young adults who survive 5 years after diagnosis face an ongoing higher risk for death.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 26, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
BOSTON and ATLANTA, Aug. 26, 2022 -- (Healthcare Sales & Marketing Network) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parki... Biopharmaceuticals, Oncology, FDA Inhibikase Therapeutics, imatinib , Chronic Myelogenous Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2022 Category: Pharmaceuticals Source Type: news

Cancer: 'Extremely worrying' people don't know the common symptoms of leukaemia - signs
CANCER is a condition that can affect any part of the body, from the brain to the stomach, and from the bowel to the skin. When cancer strikes, it is important to take action as soon as possible in order to save a life. However, the key to spotting cancer lies in knowing the symptoms, an area which charities are growing increasingly concerned about. (Source: Daily Express - Health)
Source: Daily Express - Health - August 25, 2022 Category: Consumer Health News Source Type: news